Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...

Court cites lack of inventiveness and failure to meet reproducibility standards | Decision part of broader international ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

“Third, Biogen’s been running on fumes while it works on its Alzheimer’s drug, but the fumes, basically a very good MS drug, in a crowded field, aren’t enough. Not with the unmet projectio ...

Biogen’s top-line remains heavily reliant on its multiple sclerosis (MS) portfolio, which accounts for over 60% of 2024 revenue, including royalties from Ocrevus. Piper Sandler flagged several ...

There has also been a shift in treatment preferences over the years in MS towards B-cell depleting therapies like Roche's (OTCQX:RHHBY) Ocrevus (Biogen earned $346.8 million in Q3 from Ocrvus ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

Jane Grogan, Ph.D., took over Biogen’s research department in the wake of large-scale layoffs. Now, a little more than a year later, she’s making cuts of her own. The neuro-focused biotech is ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, ...

Stock analysts at Wedbush lowered their Q4 2024 earnings estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biotechnology ...